A Highly Predictive MicroRNA Panel for Determining Delayed Cerebral Vasospasm Risk Following Aneurysmal Subarachnoid...

Area of Science:

• Neuroscience
• Biomarker Discovery
• Molecular Biology

Background:

• Delayed cerebral vasospasm (DCV) is a common complication of aneurysmal subarachnoid hemorrhage (aSAH), leading to significant neurological disability.
• Currently, no validated biomarkers exist to predict DCV risk in aSAH patients.
• MicroRNAs (miRNAs) are implicated in aSAH pathogenesis and are detectable in biofluids.

Purpose of the Study:

• To identify novel biomarkers for predicting DCV risk in aSAH patients.
• To develop and validate a miRNA-based prediction model for DCV.
• To assess the clinical utility of miRNA profiling for early DCV risk stratification.

Main Methods:

• A custom TaqMan Low Density Array miRNA panel was used to analyze 47 brain and vasculature injury-related miRNAs.
• CSF and plasma samples were collected from 31 aSAH patients (with/without DCV) and 8 healthy controls at 3 and 7 days post-aSAH.
• A two-cohort approach (training and testing) was employed for miRNA identification and model validation.

Main Results:

• Differential miRNA expression patterns were observed in aSAH patients with DCV compared to those without, detectable as early as 3 days post-aSAH.
• Seven specific miRNAs were identified as reliable predictors of DCV risk.
• A prediction model using 19 miRNAs achieved 87% accuracy in predicting DCV risk in an independent testing cohort.

Conclusions:

• A novel miRNA panel effectively predicts DCV risk in aSAH patients.
• Early identification of DCV risk via miRNA profiling has significant potential for clinical management and improving patient outcomes.
• This miRNA-based approach offers a promising tool for proactive intervention in aSAH care.